公告发布公告，三生国健及关联方三生制药、沈阳三生就707 项目（PD1/VEGF）与辉瑞达成授权协议，首付款与里程碑最高可达60.5 亿美金，其中三生国健分配30%。707 临床数据优异、研发进度靠前，我们看好707 项目的适应症拓展、全球开发及商业化潜力，维持“增持”评级。海外授权首付款+里程碑合计最高60.5 亿美元，三生国健分配比例30%1）截止24 年底三生制药合计控制三生国健80.88%...
Source Link公告发布公告，三生国健及关联方三生制药、沈阳三生就707 项目（PD1/VEGF）与辉瑞达成授权协议，首付款与里程碑最高可达60.5 亿美金，其中三生国健分配30%。707 临床数据优异、研发进度靠前，我们看好707 项目的适应症拓展、全球开发及商业化潜力，维持“增持”评级。海外授权首付款+里程碑合计最高60.5 亿美元，三生国健分配比例30%1）截止24 年底三生制药合计控制三生国健80.88%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.